Palatin Technologies (PTN) Total Liabilities (2011 - 2026)
Palatin Technologies' (PTN) quarterly Total Liabilities came in at $2.6 million in Q1 2026, down 73.97% on a YoY basis from $10.1 million in Q1 2025, and down 59.25% quarter-over-quarter from $6.5 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Total Liabilities (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Total Liabilities for 16 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 73.97% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (down 73.97% YoY), and the FY2025 full-year result was $8.0 million, down 25.89% from the prior year.
- Total Liabilities eased to $2.6 million in Q1 2026 per PTN's latest filing, from $6.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $24.5 million in Q4 2023 and bottomed at $2.6 million in Q1 2026.
- Historically, Total Liabilities has averaged $13.2 million across 5 years, with a median of $11.1 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities jumped 56.82% in 2023, then plunged 73.97% in 2026.
- Over 5 years, Total Liabilities stood at $15.6 million in 2022, then surged by 56.82% to $24.5 million in 2023, then tumbled by 56.39% to $10.7 million in 2024, then plunged by 39.56% to $6.5 million in 2025, then plunged by 59.25% to $2.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.6 million, $6.5 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 2.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.63 Mn |
| Dec 31, 2025 | 6.46 Mn |
| Sep 30, 2025 | 8.22 Mn |
| Jun 30, 2025 | 8.04 Mn |
| Mar 31, 2025 | 10.12 Mn |
| Dec 31, 2024 | 10.69 Mn |
| Sep 30, 2024 | 11.10 Mn |
| Jun 30, 2024 | 10.85 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | 24.52 Mn |
| Sep 30, 2023 | 16.14 Mn |
| Jun 30, 2023 | 19.66 Mn |
| Mar 31, 2023 | 16.02 Mn |
| Dec 31, 2022 | 15.63 Mn |
| Sep 30, 2022 | 19.19 Mn |
| Jun 30, 2022 | 19.80 Mn |
| Mar 31, 2022 | 15.73 Mn |
| Dec 31, 2021 | 17.80 Mn |
| Sep 30, 2021 | 16.76 Mn |
| Jun 30, 2021 | 17.65 Mn |